Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population

European Journal of Clinical Pharmacology

Volumn 70, Issue 1, 2014, Pages 47-56

  Krishna Kumar, Dhakchinamoorthi ^a   Shewade, Deepak Gopal ^a   Loriot, Marie Anne ^b,c   Beaune, Philippe ^b,c   Balachander, Jayaraman ^a   Sai Chandran, B V ^a   Adithan, Chandrasekaran ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b Sorbonne University in Paris   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Genotype; Pharmacogenetic algorithm; Polymorphisms; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGE; ALGORITHM; ARTICLE; BODY WEIGHT; CYP2C9 GENE; CYP4F2 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GGCX GENE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; MITRAL VALVE STENOSIS; PHARMACOGENETICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATIC HEART DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE;

ADULT; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CARBON-CARBON LIGASES; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; INDIA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84891888818     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1581-x     Document Type: Article

References (48)

1. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE (2004) Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:401S-428S (Pubitemid 39297960)
2. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:338S-400S (Pubitemid 39302602)
3. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA et al (2004) Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:513S-548S (Pubitemid 39302604)
4. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N et al (2004) Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:457S-482S (Pubitemid 39297961)
5. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ (2004) Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:429S-456S (Pubitemid 39302603)
6. Horowitz B, Minor P, Morgenthaler JJ, Burnouf T, McIntosh R, Padilla A et al (2004) WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser 924:1-232
7. Schalekamp T, Brasse BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H et al (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80:13-22 (Pubitemid 43964915)
8. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329-2333 (Pubitemid 41510803)
9. Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH et al (2008) Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 84:83-89 (Pubitemid 351861488)
10. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M et al (2008) Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9:169-178 (Pubitemid 351566941)
11. King CR, Deych E, Milligan P, Eby C, Lenzini P, Grice G et al (2010) Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 104:750-754
12. Singh O, Sandanaraj E, Subramanian K, Lee LH, Chowbay B (2011) Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab Pharmacokinet 26:130-136
13. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ (2010) Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11:781-791
14. Reich D, Thangaraj K, Patterson N, Price AL, Singh L (2009) Reconstructing Indian population history. Nature 461:489-494
15. Abraham BK, Adithan C, Mohanasundaram J, Shashindran CH, Koumaravelou K, Asad M (2001) Genetic polymorphism of CYP2D6 in Tamil population. Eur J Clin Pharmacol 56:849-850 (Pubitemid 33788559)
16. Naveen AT, Adithan C, Soya SS, Gerard N, Krishnamoorthy R (2006) CYP2D6 genetic polymorphism in South Indian populations. Biol Pharm Bull 29:1655-1658 (Pubitemid 44166369)
17. Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK et al (2005) CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol 19:101-105 (Pubitemid 40204352)
18. Krishnakumar D, Gurusamy U, Dhandapani K, Surendiran A, Baghel R, Kukreti R et al (2012) Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Fundam Clin Pharmacol 26:295-306
19. Barrett JC (2009) Haploview: visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 2009(10). doi: 10.1101/pdb.ip71
20. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP et al (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116:2563-2570 (Pubitemid 350179221)
21. Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MA (2011) Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis 46:147-150
22. Cini M, Legnani C, Cosmi B, Guazzaloca G, Valdre L, Frascaro M et al (2012) A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol 68:1167-1174
23. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL (2004) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91:87-94 (Pubitemid 38111225)
24. Gan GG, Phipps ME, Lee MM, Lu LS, Subramaniam RY, Bee PC et al (2011) Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann Hematol 90:635-641
25. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-764
26. Miao L, Yang J, Huang C, Shen Z (2007) Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 63:1135-1141 (Pubitemid 350112769)
27. Ohno M, Yamamoto A, Ono A, Miura G, Funamoto M, Takemoto Y et al (2009) Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol 65:1097-1103
28. Oner OG, Langaee TY, Feng H, Buyru N, Ulutin T, Hatemi AC et al (2008) VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol 64:889-894
29. Pavani A, Naushad SM, Mishra RC, Malempati AR, Pinjala R, Kumar TR et al (2012) Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. Pharmacogenomics 13:869-878
30. Shahin MH, Khalifa SI, Gong Y, Hammad LN, Sallam MT, El SM et al (2011) Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 21:130-135
31. Shrif NE, Won HH, Lee ST, Park JH, Kim KK, Kim MJ et al (2011) Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol 67:1119-1130
32. Takeuchi F, Kashida M, Okazaki O, Tanaka Y, Fukuda S, Kashima T et al (2010) Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients. Circ J 74:977-982
33. Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R et al (2006) A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 80:346-355 (Pubitemid 44479750)
34. Verde Z, Ruiz JR, Santiago C, Valle B, Bandres F, Calvo E et al (2010) A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One 5:e11210
35. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S et al (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784-792
36. Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT et al (2008) Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta 396:76-79
37. Wells PS, Majeed H, Kassem S, Langlois N, Gin B, Clermont J et al (2010) A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res 125:e259-e264
38. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr et al (2007) Estimation of warfarin maintenance dose based on VKORC1 (-1639 G > A) and CYP2C9 genotypes. Clin Chem 53:1199-1205 (Pubitemid 47020974)
39. Kumar DK, Shewade DG, Surendiran A, Adithan C (2013) Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population. J Pharmacol Pharmacother 4:53-58
40. Lal S, Sandanaraj E, Jada SR, Kong MC, Lee LH, Goh BC et al (2008) Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br J Clin Pharmacol 65:260-264 (Pubitemid 351171275)
41. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293 (Pubitemid 40740552)
42. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI et al (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-1027
43. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C et al (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23-34 (Pubitemid 46421137)
44. Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahe I, Legendre C et al (2010) Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 87:57-64
45. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433
46. Wang M, Lang X, Cui S, Fei K, Zou L, Cao J et al (2012) Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial. Int J Med Sci 9:472-479
47. Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamaguchi T et al (2012) Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 76:1840-1847
48. Chan SL, Thalamuthu A, Goh BC, Chia KS, Chuah B, Wong A et al (2011) Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population. Pharmacogenet Genomics 21:35-41